Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) and DBV Technologies (NASDAQ:DBVT – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.
Profitability
This table compares Arrowhead Pharmaceuticals and DBV Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arrowhead Pharmaceuticals | -47.79% | -60.06% | -17.37% |
| DBV Technologies | -3,506.53% | -119.33% | -84.43% |
Insider and Institutional Ownership
62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 1.1% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arrowhead Pharmaceuticals | $829.45 million | 9.87 | -$1.63 million | ($2.25) | -25.84 |
| DBV Technologies | $5.64 million | 100.67 | -$146.95 million | ($3.51) | -2.57 |
Arrowhead Pharmaceuticals has higher revenue and earnings than DBV Technologies. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and target prices for Arrowhead Pharmaceuticals and DBV Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arrowhead Pharmaceuticals | 1 | 3 | 10 | 0 | 2.64 |
| DBV Technologies | 1 | 0 | 5 | 0 | 2.67 |
Arrowhead Pharmaceuticals presently has a consensus price target of $98.31, indicating a potential upside of 69.12%. DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 437.10%. Given DBV Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe DBV Technologies is more favorable than Arrowhead Pharmaceuticals.
Volatility and Risk
Arrowhead Pharmaceuticals has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -1.04, suggesting that its share price is 204% less volatile than the S&P 500.
Summary
Arrowhead Pharmaceuticals beats DBV Technologies on 9 of the 13 factors compared between the two stocks.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
